The use is described of both (i) ranitidine bismuth citrate and (ii) one or more Helicobacter pylori-inhibiting antibiotics in treating or preventing gastrointestinal disorders. Pharmaceutical compositions containing both (i) and (ii) and methods for the preparation of pharmaceutical compositions containing (i) and (ii) are also described.

A medicament which contains the histamine H2 antagonist ranitidine N-[2-[[[5-(dimethylamino)methyl]-2- furanyl]methyl]thio]ethyl-N-methyl-2-nitro-11- ethenediamine in a new crystal form is produced. The medicament is obtained by selective crystallization of ranitidine and subsequent mixing with pharmaceutically acceptable carrier substances and where appropriate further pharmaceutically active substances.

Podstatu ntvo s tvonranitidinem a komplexem vizmutu s karboxylovou kyselinou zvolenou ze souboru tvono kyselinou citronovou a kyselinou vinnou nebo solv to soli. Soust ntvo takzpob ppravy uvedenh sola farmaceutickprostdek ktertyto soli obsahuje.

The use is described of both (i) ranitidine bismuth citrate and (ii) a non-steroidal anti-inflammatory drug in treating or preventing inflammatory conditions and for analgesia. Pharmaceutical compositions containing both (i) and (ii) and methods for the preparation of pharmaceutical compositions containing (i) and (ii) are also described.

Compounds of the formula II are converted into a histamine H2 antagonist which contains a -NHC(=CHNO2)- NHCH3 terminal group for example ranitidine by a reaction with a suitable amine. The compounds of the formula II in which R1 is C1-C4-alkyl are prepared by reacting a compound of the formula I in which Q is hydrogen or a cation with an alkylating agent. The compound of the formula I is prepared by reacting methyl isothiocyanate with the carbanion of nitromethane (which is preferably prepared...